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                NEED OF NEW ANTIBIOTICS 
          
                 The development of antibiotic resistance in bacteria is a good 
example of natural selection, to the point that these resistance bacteria 
have been described as superbugs. 
It’s obvious the need to design new therapeutic strategies to solve this 
global health problem appeared because of the misuse and overuse of 
antibiotics.  
This work put forward as promising candidates Antimicrobial peptides 
(APs), ancient molecules involved in many defense mechanisms conserved 
during a lot of generations in a wide range of organisms, because nature 
can always teach us. 
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If during the long course of ages and under varying conditions of 
life, organic beings vary at all in the several parts of their 
organization, (…) then, considering the infinite complexity of the 
relations of all organic beings to each other and to their conditions 
of existence, causing an infinite diversity in structure, constitution, 
and habits, to be advantageous to them (…) But, if variations useful 
to any organic being do occur, assuredly individuals thus 
characterized will have the best chance of being preserved in the 
struggle for life; and from the strong principle of inheritance they will 
tend to produce offspring similarly characterized. This principle of 
preservation, I have called, for the sake of brevity, Natural Selection.”    
                 Charles Darwin (1859). The Origin of Species. 
 
 
 
 
WHY APS?    
                                                            
APs are small cationic peptides, effector molecules of the innate immune system. They are 
present in the first barriers of all living organisms: skin, mucosa, epithelia... and that’s 
why these tissues are almost never infected.  
They are expressed in a variety of cell types: leucocytes, such as monocytes and 
neutrophils, epithelia cells, mast cells, so on, and their expression could be constitutive or 
induced.  
 
Nowadays more than 2000 APs have been reported from different organisms and with 
different activities. Understanding the relationship between structure and activity may 
facilitate the rational design of novel antimicrobial agents.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Due to their amphipatic properties, caused by their positive charge and nearly 50% of 
the amino acids hydrophobic, antimicrobial peptides show broad antimicrobial activity: 
antibacterial, antiviral, antifungal, antiparasitic and so on. APs can bind to anionic 
components of microorganisms membrane, causing a disruption on it and promoting 
death. There are several mechanisms proposed for the permeabilization of membrane, 
e.g.  Carpet model, barrel stave  or toroidal model. 
 
Furthermore, APs have an impressive variety of additional activities related with some 
immunity processes, such as neutralization of endotoxins released from macrophags 
and monocytes, chemotaxis , promotion of angiogenesis and wound repair.  
 
 Overview of different activities of APs and some examples. Information source: APD (Antimicrobial peptide 
database). 
Nº Activity Example AP 
1762 Antibacterial 
Defensins 
Cathelicidin derived peptides: Protegrin-PG1 
773 Antifungal 
Cathelicidin derived:  BMAP-27, Indolicidin.  
 Histatins. Aurein 
135 Antiviral (VIH, VHS, VSV) 
α- defensin HNP1, Human β- and synthetic θ- 
defensin  (Retrocyclin 2) 
48 Antiparasitic BMAP-18,  PMAP-23  
22 Antiinsecticidal Ponericin 
3 Anti-protist EcAMP1 
145 Anticancer Buforin IIb (derived from histone H2A) 
41 Chemotactic activity 
For neutrophils: PR-39 
For T cells: HNP-1, LL-37 
For monocytes: ProBac 7, Defensins 
Compound/ peptide Company Mode of use Clinical use Phase 
Polysporin 
(Gramicidin,polymixin, 
Bacitracin) 
Johnson & Johnson 
Topical, 
ophthalmologic 
Triple antibiotic 
therapy ointment 
Approved FDA 
Primecrolimus Valent Bermuda Topical Atopic dermatitis 
Approved FDA 
(2001) 
Polymyxin B Some Multiple forms Gram – infections Approved FDA 
Daptomycin Cubist Pharmaceutical Intravenous 
Infections by Gram + / 
MRSA1 
Approved FDA 
(2003/2013) 
Micafungin Astelles Pharma Inc. Multiple forms Antifungical 
Approved FDA 
(2005) 
Fuzeon Hoffmann-La Roche Subcutaneous Against HIV replication 
Approved FDA 
(2003) 
Pexiganan  
  MSI-78 
Acces Pharmaceuticals Topical Diabetic ulcers III 
MBI-226 Biowest therapeutic Inc Topical Acne II 
PMX 30063 Polymedix, Inc. Topical 
Acute bacterial skin 
infections due MSSA2 
II 
Lactoferrin 
hLFf1-11 
AM-Pharma Intravenous 
Fungal and bacterial 
infections in HSCT 
I/II 
Colistidin Park Davis s Oral Infection due to MSAB 
Synergism 
colistidin+ 
Rifampicin ( p. 
III) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APs seem to figure out the resistance problem because, unlike conventional 
antibiotics, APs do not have only a single primary target and a single mode of 
action, each AP could show different modes of action in each microorganism. In 
addition, they do not need to bind to specific receptors on the membrane surface. 
Nevertheless, they show some unresolved problems that don’t let them go into 
clinical market.   
APs AS NEW ANTIBIOTIC DRUGS 
   
Conventional 
antibiotics 
Antimicrobial peptides 
Activity Only Anti-bacteria 
Broad spectrum of activity: bacteria, fungi, virus… 
Immunomodulatory properties: chemotactic, 
endotoxin neutralization, wound repair, 
angiogenesis… 
 Antibacterial 
activity 
Single primary target 
and mode of action. 
4-24 h aprox 
Differet mode of action in each bacteria 
Minutes 
Resistance 
development 
High Few 
Pharmacodinamic 
Good bioavailibity and 
biodistribution 
Low oral bioavailbilitySusceptibility to salt, pH and 
serum 
Poor specific biodistribution 
hepatic/renal clearance. 
Pharmacokinetic Vary 
Short half-life  
Proteolytic degradation 
Toxicology Low High 
Manufacturing 
cost 
Low High 
 
 
The main hurdless that have impeded the development of such peptides and their clinical 
use are (1) the toxicity against mammalian cells, (2) high susceptibly to proteases and (3) 
high manufacturing cost.  
Owing to the development in solid phase peptide synthesis is becoming easer and the 
manufacturing cost cheaper. Several strategies like peptidomimetics, formulation of 
prodrugs and substitution of L-amino acids to D-aminoacids have been evaluated to 
enhance the stability and improve toxicity in their administration. Once improved that, 
maybe in a long term, it would be interesting to address methods of formulation for 
systemic or oral use.  
 
It is important to note that antimicrobial peptides could enter into therapeutics by various 
strategies, such as combination of peptides and administration as adjuvants to promote a 
synergistic effect and enhance the innate immune response.  
 
Needless to say, APs are excellent candidate molecules that must be studied in depth to 
understand the basis of their limitations. It is important address future studies to the 
development of safe, stable and effective therapeutic strategies with antimicrobial for 
bacterial infections and other human diseases.  
 
FUTURE PROSPECTIVE AND CONCLUSIONS  
 
 
Databases information 
Activities of Antimicrobial Peptides. APs not only show antimicrobial activities, but they are also involved in some 
biological processes related with immunity. 
Figure modified from Fabiola Cost, et. al. Elsevier Science Direct, Peptides 36 (2011) and Yuping Lai, et. al. Trends in 
Immunology (2009)  
APs in clinical use and development. Abbreviations: MSSA- Multiresistant Staphylococcus aureus; HSCT- Haematopoietic stem cells transplant; 
MRAB- Multidrug-Resistant Acinetobacter Baumannii; MRSA- Methilicidin-resistant Staphylococus aureus  
 
